Two clinical studies were undertaken to evaluate the immunogenicity of an adult-type dTpa
booster vaccine (Boostrix™ by GlaxoSmithKline Biologicals). Blood samples taken prior to …

The aim of this assessor-blinded trial was to compare the immunogenicity and reactogenicity
of a candidate diphtheria, tetanus toxoids and acellular pertussis vaccine with reduced …

A single blinded randomized controlled trial to compare the reactogenicity and
immunogenicity of adult formulated dTpa and monovalent pa vaccines with a licensed Td …

We compared immunogenicity and reactogenicity of a single dose of DTaP vaccine
(containing tetanus and diphtheria toxoids and four acellular pertussis antigens) with …

There is increasing interest in prevention of pertussis in adults by vaccination, but little is
known about the duration of the antibody response to pertussis, diphtheria or tetanus in …

Abstract▴ The reduced-antigen combined diphtheria-tetanus-acellular pertussis vaccine
(dTpa) is intended for use as a booster dose in individuals aged≥ 4 years.▴ A single dose …

The widespread use of whole-cell pertussis vaccines in the second half of the 20th century
have reduced the incidence of the disease significantly. However, in some countries …

Introduction: Older children and adults, susceptible to pertussis because of waning
immunity, may serve as a reservoir of infection, leading to severe disease among young …

BACKGROUND: Increasing incidence of pertussis in adolescents and adults has stimulated
the development of safe and immunogenic acellular pertussis vaccines for booster …

A trial to compare the reactogenicity and immunogenicity of a reduced antigen content
diphtheria–tetanus–acellular pertussis (dTpa) vaccine with diphtheria–tetanus–whole-cell …